Blog Posts - 19 November 2018
The demands of today’s healthcare ecosystem require greater focus and attention from key stakeholders than ever before. Meeting today’s complex challenges requires progressive thinking, effectively applied by those who understand where the market is trending and those who are willing to challenge the status-quo next generation solutions. The need to cost-effectively accelerate the time-to-market of new therapies has never been higher. Post launch real-world evidence is required to optimize patient access. These market factors are the stimulus for this article.
The barriers to efficiently introduce new therapies are formidable. Many commercially available data sets do not contain the broad range of clinical data required to identify point of patient care opportunities for required research. Securing study sites with the appropriate patients who meet protocol criteria is often a slow and an expensive process. Accelerating the time to market requires the efficiency of a data-driven resource that seamlessly facilitates clinical trial recruitment to optimize research. Fully integrated electronic health record data derived from a multi-specialty physician base can speed the process of securing the required elements to accelerate time to market.
Obtaining RWE is essential to enhancing access, but doing so requires a wide range of resources, skills and relationships. An effective path to optimized market access starts with a more efficient means to gather RWE. The combination of a broad, diverse set of clinical data with customizable analytic tools, integrated with associated services, can provide the actionable insights needed to ensure the success of retrospective and observational studies, safety surveillance, and reimbursement, and ultimately secure appropriate medication access.
It has been estimated that a typical healthcare professional in the U.S. is exposed to 4,000 ads per day. Combined with patients increasing demand for access to their own healthcare cost data, including medication, and their reliance on their health care providers of to provide the necessary context; it is understandable that providers are overwhelmed.
The ability for BioPharma companies to provide the appropriate product and patient support communication within a healthcare provider’s daily workflow is essential to drive appropriate medication consideration and enhanced patient adherence to their individual care plan.
BioPharma companies can identify opportunities to drive improvement against all three of these challenges and more. Veradigm is the integrated data systems and services company that combines data-driven clinical insights with actionable solutions.
Veradigm is positively impacting time-to-market for new therapeutic market entries by identifying appropriate patients, then combining that clinical insight with outreach and recruiting tools to determine prospective study sites and facilitate the recruitment of qualified providers through their daily workflow.
Delivering the industry’s largest commercially available ambulatory EHR dataset, Veradigm generates real world evidence, including de-identified clinical data combined with an innovative analytic technology platform for outcomes research, helping BioPharma companies to better understand the patient journey across the spectrum of care, and into their daily lives.
Veradigm supports BioPharma companies with a broad range of dynamic media solutions to effectively and appropriately communicate key messages to healthcare providers within their existing daily workflow.
For more information on how Veradigm solutions can help you to capitalize on these and other healthcare opportunities, please contact Veradigm at 1-833-VERADGM or visit www.veradigmhealth.com.